Publications (57) Jesús Corral Jaime publications

filter_list

2023

  1. Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives

    Lung Cancer, Vol. 179

  2. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

    Thrombosis Research, Vol. 232, pp. 133-137

  3. Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

    Journal of Translational Medicine, Vol. 21, Núm. 1

2022

  1. ALK and ROS-1 NSCLC patients treatment approach based on genomic profile by liquid biopsy

    Precision Cancer Medicine

  2. SEOM clinical guidelines for the prophylaxis of infectious diseases in cancer patients (2021)

    Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 724-732

  3. Withdrawal of dacomitinib treatment due to absence of toxicities is not justified

    Future Oncology

2021

  1. Delta-radiomics signature for prediction of survival in advanced nsclc patients treated with immunotherapy

    Proceedings - International Symposium on Biomedical Imaging

  2. Molecular biomarkers in early stage lung cancer

    Translational Lung Cancer Research, Vol. 10, Núm. 2, pp. 1165-1185

  3. Present, past, and future of the connection between SAHS and cancer

    Open Respiratory Archives

  4. The patient's perspective on treatment with dacomitinib: Patient-reported outcomes from the Phase III trial ARCHER 1050

    Future Oncology, Vol. 17, Núm. 7, pp. 783-794

  5. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

    Drugs, Vol. 81, Núm. 2, pp. 257-266

2020

  1. Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?

    Lung Cancer, Vol. 144, pp. 76-84

  2. Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study

    Lung Cancer, Vol. 147, pp. 137-142

  3. High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1

    European Journal of Cancer, Vol. 141, pp. 193-198

  4. Immune Checkpoint Inhibitors for the Therapy of Thymoma

    JTO Clinical and Research Reports, Vol. 1, Núm. 1

  5. PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice

    Clinical Cancer Research, Vol. 26, Núm. 16, pp. 4186-4197

  6. Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients

    Clinical Chemistry and Laboratory Medicine, Vol. 58, Núm. 8, pp. 1341-1348

  7. Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

    Journal of Thoracic Oncology

  8. Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours

    British Journal of Cancer, Vol. 122, Núm. 9, pp. 1324-1332

2019

  1. A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study

    Investigational New Drugs, Vol. 37, Núm. 1, pp. 98-108